Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nucleic Acid Research Institute

Executive Summary

Kodak leaving R&D joint venture with ICN. Under the exit agreement ICN retains all drugs in research, scientific personnel, lab equipment and facilities. NARI was formed in 1985. Kodak, which recently acquired drug R&D capability with the acquisition of Sterling, previously owned 5% of ICN and 10% of ICN subsidiary Viratek. Those positions were sold in March 1987.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel